Sands Capital Life Sciences Pulse Fund II, L.P.

Sands Capital Life Sciences Pulse Fund II, L.P. is listed in filings as 10% Owner at Inhibikase Therapeutics, Inc.. This profile follows SEC Form 4 activity through Nov 24, 2025, including purchase activity. Recent filings connect the profile to Inhibikase Therapeutics, Inc. (IKT). The current snapshot covers public activity from Nov 24, 2025. Reported amounts are shown as $3.0M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.